Top

Published in:

Open Access 01-12-2014 | Review

The role of glucagon on type 2 diabetes at a glance

Author: Amélio F Godoy-Matos

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Abstract

The opposite effects of insulin and glucagon in fuel homeostasis, the paracrine/endocrine inhibitory effects of insulin on glucagon secretion and the hyperglucagonemia in the pathogenesis of type 2 diabetes (T2D) have long been recognized. Inappropriately increased alpha-cell function importantly contributes to hyperglycemia and reflects the loss of tonic restraint normally exerted by high local concentrations of insulin on alpha-cells, possibly as a result of beta-cell failure and alpha-cell insulin resistance, but additional mechanisms, such as the participation of incretin hormones in this response, have also been suggested. Three classes of drugs already available for clinical use address the abnormalities of glucagon secretion in T2D, namely, the GLP-1 receptor agonists (GLP-1RA), the inhibitors of dipeptidyl peptidase-4 (DPP-4i) and the amylin agonist pramlintide; it has been proposed that the glucagonostatic and insulinotropic effects of GLP-1RA equally contribute to their hypoglycemic efficacy. In this review, the control of glucagon secretion and its participation in T2D pathogenesis are summarized.

Available only for authorised users

Murlin JR, Clough HD, Gibbs CBF, Stokes AM: Aqueous extracts of the pancreas. 1. Influence on the carbohydrate metabolism of depancreatized animals. J Biol Chem. 1923, 56: 253-296.

Sutherland EW, De Duve C: Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J Biol Chem. 1948, 175: 663-674.PubMed

Unger RH, Eisentraut AM, Mc CM, Keller S, Lanz HC, Madison LL: Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med. 1959, 102: 621-623.CrossRefPubMed

Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P: Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?. Diabetes Obes Metab. 2011, 13 (Suppl 1): 95-105.CrossRefPubMed

Gromada J, Franklin I, Wollheim CB: Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007, 28: 84-116.CrossRefPubMed

Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB: Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes. 2005, 54: 1808-1815.CrossRefPubMed

Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebina Y, Wheeler MB, Braun M, Wang Q: Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab. 2006, 3: 47-58.CrossRefPubMed

Bansal P, Wang Q: Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab. 2008, 295: E751-E761.CrossRefPubMed

Osundiji MA, Evans ML: Brain control of insulin and glucagon secretion. Endocrinol Metab Clin North Am. 2013, 42: 1-14.CrossRefPubMed

10.

Tuduri E, Marroqui L, Soriano S, Ropero AB, Batista TM, Piquer S, Lopez-Boado MA, Carneiro EM, Gomis R, Nadal A, Quesada I: Inhibitory effects of leptin on pancreatic alpha-cell function. Diabetes. 2009, 58: 1616-1624.PubMedCentralCrossRefPubMed

11.

Gedulin BR, Rink TJ, Young AA: Dose–response for glucagonostatic effect of amylin in rats. Metabolism. 1997, 46: 67-70.CrossRefPubMed

12.

Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132: 2131-2157.CrossRefPubMed

13.

Heller RS, Aponte GW: Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7–36) amide. Am J Physiol. 1995, 269: G852-G860.PubMed

14.

Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D’Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, Dotta F: A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012, 55: 3262-3272.CrossRefPubMed

15.

Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS: Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem. 2008, 56: 841-851.PubMedCentralCrossRefPubMed

16.

Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F: Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes. 1996, 45: 257-261.CrossRefPubMed

17.

Heller RS, Kieffer TJ, Habener JF: Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes. 1997, 46: 785-791.CrossRefPubMed

18.

De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zang E, Reimann F, Rosengren AH, Shibasaki T, Gribble F, Renström E, Seino S, Eliasson L, Rorsman P: GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab. 2010, 11: 543-553.PubMedCentralCrossRefPubMed

19.

de Heer J, Rasmussen C, Coy DH, Holst JJ: Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008, 51: 2263-2270.CrossRefPubMed

20.

Muoio DM, Newgard CB: Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008, 9: 193-205.CrossRefPubMed

21.

Lim M, Park L, Shin G, Hong H, Kang I, Park Y: Induction of apoptosis of Beta cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Ann N Y Acad Sci. 2008, 1150: 311-315.CrossRefPubMed

22.

Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986, 29: 46-52.CrossRefPubMed

23.

Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986, 63: 492-498.CrossRefPubMed

24.

Meier JJ, Nauck MA: Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes. 2010, 59: 1117-1125.PubMedCentralCrossRefPubMed

25.

Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ: The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003, 88: 4897-4903.CrossRefPubMed

26.

An Z, Prigeon RL, D’Alessio DA: Improved glycemic control enhances the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2013, 98: 4702-4708.CrossRefPubMed

27.

Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S: Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011, 34 (Suppl 2): S251-S257.PubMedCentralCrossRefPubMed

28.

Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK: Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010, 95: 3309-3317.CrossRefPubMed

29.

Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM: Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest. 1970, 49: 837-848.PubMedCentralCrossRefPubMed

30.

Menge BA, Gruber L, Jorgensen SM, Deacon CF, Schmidt WE, Veldhuis JD, Holst JJ, Meier JJ: Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes. 2011, 60: 2160-2168.PubMedCentralCrossRefPubMed

31.

Borghi VC, Wajchenberg BL, Cesar FP: Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Metabolism. 1984, 33: 1068-1074.CrossRefPubMed

32.

Ferrannini E, Muscelli E, Natali A, Gabriel R, Mitrakou A, Flyvbjerg A, Golay A, Hojlund K: Relationship between insulin S, cardiovascular disease risk project I: association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia. 2007, 50: 2342-2347.CrossRefPubMed

33.

Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, Herrera PL, Polonsky KS, McGuinness OP, Kulkarni RN: Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 2009, 9: 350-361.PubMedCentralCrossRefPubMed

34.

Unger RH, Orci L: Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A. 2010, 107: 16009-16012.PubMedCentralCrossRefPubMed

35.

Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK: The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2011, 300: E1038-E1046.CrossRefPubMed

36.

Dor Y, Glaser B: beta-cell dedifferentiation and type 2 diabetes. N Engl J Med. 2013, 368: 572-573.CrossRefPubMed

37.

Unger RH, Cherrington AD: Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012, 122: 4-12.PubMedCentralCrossRefPubMed

38.

Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH: Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes. 2011, 60: 391-397.PubMedCentralCrossRefPubMed

39.

Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahren B: Fibroblast growth factor 21 (FGF21) and glucagon like-peptide 1 contribute to diabetes resistance in glucagon receptor deficient mice. Diabetes. 2014, 63: 101-110.CrossRefPubMed

40.

D’Alessio DA: Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target?. Diabetes. 2010, 59: 1572-1574.PubMedCentralCrossRefPubMed

41.

Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ: The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010, 59: 1765-1770.PubMedCentralCrossRefPubMed

42.

Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004, 89: 2078-2084.CrossRefPubMed

43.

Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004, 53: 1187-1194.CrossRefPubMed

44.

Kielgast U, Krarup T, Holst JJ, Madsbad S: Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011, 34: 1463-1468.PubMedCentralCrossRefPubMed

Title: The role of glucagon on type 2 diabetes at a glance
Author: Amélio F Godoy-Matos
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/1758-5996-6-91

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The role of glucagon on type 2 diabetes at a glance

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study

Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study

The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice

High serum phosphate and triglyceride levels in smoking women and men with CVD risk and type 2 diabetes

Realistic changes in monounsaturated fatty acids and soluble fibers are able to improve glucose metabolism

Differential association between obesity and coronary artery disease according to the presence of diabetes in a Korean population

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page